Claris Ventures

NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.

Kither Biotech s.r.l. is a pharmaceutical company based in Turin, Italy, focused on the research and development of drugs and therapies for pulmonary diseases. Founded in 2011, the company is dedicated to addressing unmet medical needs in chronic inflammatory conditions. Its main products include the KIT2014 peptide, developed internally for the treatment of cystic fibrosis, which has received Orphan Drug designation from the European Medicines Agency and is currently in the pre-clinical development phase. Additionally, Kither is advancing the development of a molecule known as CL27, aimed at treating chronic obstructive pulmonary diseases and allergic asthma, and is preparing to enter its pre-clinical phase. Through its innovative research efforts, Kither Biotech seeks to provide effective treatments for patients suffering from various respiratory diseases.

Resalis Therapeutics treats metabolic disorders, including nash, obesity, and cancer. They provide focused on the development of oligonucleotide anti-sense therapies. Their customers contact them through address, phone, mail, and online applications.

NeoPhore is a provider of novel small molecule therapies intended to treat cancer through stimulation of the immune system.The company's small molecule therapies target genetic mechanisms in order to create neoantigen which is known to stimulate the immune system and potentially be a weak spot in a tumor cell's defense mechanisms, enabling cancer patients to get treated and achieve improved clinical outcomes.

Kither Biotech s.r.l. is a pharmaceutical company based in Turin, Italy, focused on the research and development of drugs and therapies for pulmonary diseases. Founded in 2011, the company is dedicated to addressing unmet medical needs in chronic inflammatory conditions. Its main products include the KIT2014 peptide, developed internally for the treatment of cystic fibrosis, which has received Orphan Drug designation from the European Medicines Agency and is currently in the pre-clinical development phase. Additionally, Kither is advancing the development of a molecule known as CL27, aimed at treating chronic obstructive pulmonary diseases and allergic asthma, and is preparing to enter its pre-clinical phase. Through its innovative research efforts, Kither Biotech seeks to provide effective treatments for patients suffering from various respiratory diseases.